Aktis Oncology

Update in progress

AKTS (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Aktis Oncology, Inc. is a clinical-stage oncology company developing targeted radiopharmaceuticals for solid tumors. Its lead candidates are [225Ac]Ac-AKY-1189, in Phase 1b for Nectin-4–expressing tumors (including urothelial, breast, NSCLC, colorectal, and cervical cancers), and [225Ac]Ac-AKY-2519 for B7-H3–expressing tumors (e.g., prostate and lung cancers). It has licenses with Protein Innovation, TRIUMF Innovations, and Eli Lilly. Formerly HotKnot Therapeutics, renamed in 2020; founded 2020 and based in Boston.

Company score

Sentiment: -0.61; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.00; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.42; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.09; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.35; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive